Sign in
Active, not recruitingPhase 3

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Key facts

Who runs it
Abeona Therapeutics, Inc
Where
Redwood City and Worcester, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
12 people, planned
Started
2 Apr 2023
Ended
30 Sept 2025
Type of study
Interventional
Treatments tested
  • EB-101 Surgical application of RDEB wounds
Record updated
27 June 2025

Who can take part

Age
12 months and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Clinical diagnosis of DEB
  • Age 12 months and older
  • Willing and able to give consent/assent; if under the age of 18 years, guardian(s) is/are willing and able to give consent
  • (This inclusion criterion was deleted as of Amendment 1.)
  • Confirmation of DEB diagnosis (either dominant [DDEB] or recessive [RDEB] forms) by genetic testing
  • Able to undergo adequate anesthesia during EB-101 treatment
  • All women of childbearing potential must have a negative urine pregnancy test and use a reliable birth control method throughout the duration of the study
  • On stable pain medication regimen for at least 30 days prior to Screening (and through Baseline)
  • Must have at least one wound site that meets all of the following criteria:; An area ≥20 cm2,; Present for ≥6 months, and; Stage 2 wound defined as an open skin wound with partial thickness loss of dermis that has not extended through the dermis into subcutaneous tissue
  • For patients with RDEB, they must have had Vyjuvek exposure by the time of screening or positive anti-C7 antibodies at baseline
  • Patients must be willing to discontinue Vyjuvek and Filsuvez use on EB-101 treated sites until completion of the Week 24 visit

Who cannot take part

  • Active drug or alcohol addiction
  • Receipt of chemical or biological investigational therapy for the specific treatment of DEB in the 3 months prior to EB-101 application
  • The presence of medical illness expected to complicate participation and/or compromise the safety of this technique, such as active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
  • Evidence of systemic infection
  • Current evidence or a history of SCC in the area that will undergo EB-101 application
  • Hypersensitivity to vancomycin or amikacin
  • Grade 3 clinical event or laboratory abnormality at Day 0. Abnormalities such as esophageal strictures, anemia, low albumin, and pain/itch are expected in severe DEB patients, and these abnormalities will not exclude a patient
  • Medical instability limiting ability to travel to the study site or undergo EB-101 treatment
  • (This exclusion criterion was deleted as of Amendment 3.)
  • Breast-feeding
  • Inability to properly follow protocol assessments and protect keratinocyte sheet sites as determined by the PI
  • Unwillingness or inability to provide 4 skin biopsies, or patient's keratinocytes cannot be manufactured for use in EB-101 application
  • Any other circumstance where the PI believes that the patient may not be appropriate for participation in the study

Where in United States

  • Stanford UniversityRedwood City, United States
  • University of Massachusetts Medical SchoolWorcester, United States

About the trial

What the trial wants to find out

To evaluate and further characterize the safety of EB-101 (LZRSE-Col7A1 gene-corrected keratinocyte sheets with type VII collagen [C7] expression) for the treatment of large, chronic DEB wounds in new and previously EB-101 treated patients 12 months and older.

The group in the trial

  • EB-101 Surgical application of RDEB woundsTreatment being tested

    New or Previously Treated RDEB Patients

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
27 June 2025